Hikal Limited has informed the Exchange regarding a press release dated May 27, 2026, titled "Q4 & FY26 Earnings Release".
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hikal reported Q4FY26 revenue of ₹519 crore with EBITDA of ₹105 crore (20.3% margin), up from Q3's 17%. PAT was ₹14 crore, boosted by recovery in the Pharmaceuticals segment and strong volume growth in Crop Protection (revenue ₹228 crore, up 45% QoQ). FY26 full-year revenue stood at ₹1,713 crore with EBITDA margin of 12.9%. The company took a ₹47 crore exceptional impairment on its Panoli manufacturing asset. Pharmaceuticals saw sequential recovery driven by resumption of customer offtake and improved capacity utilisation, while Crop Protection recovered from inventory correction with volume traction. The Board approved a final dividend of 20% of face value (total 30% for FY26). The company flagged competitive pricing in Crop Protection due to overcapacity and Chinese competition, but expects the worst of the volume cycle to be behind it.
The sequential margin improvement to 20.3% in Q4 signals operational recovery from earlier regulatory setbacks, though FY26 margin of 12.9% reflects the tough first half. The new strategic investments in HPAPI, ADC, and Pune kilo lab are now operational, supporting a more optimistic FY27 outlook. The Panoli impairment is a one-time charge and does not affect operating performance.